LXR proteins: new target in the fight against tuberculosis?

Since treatment of normal mice with molecules that activate LXRs provided substantial protection of both new infections and infections established, the authors suggest that LXRs may provide a new target for treatments against tuberculosis.Now there is evidence that protease inhibitors can do more to combat HIV. Mayo Clinic immunologist David McKean, Ph.D., and Andrew Badley, MD, led a team that looked at what happens to T cells when people who do not take drugs against HIV AIDS

Kris Huygen and colleagues at the Scientific Institute of Public Health, Belgium, have now identified a role for LXR protein in the immune response to respiratory infections of mice with Mycobacterium tuberculosis, the bacterium that causes tuberculosis.

In the study, compared with normal mice, mice lacking both forms of LXR are more susceptible to respiratory infections with Mycobacterium tuberculosis and developed more severe disease.